James F. Polewaczyk - Feb 8, 2023 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)

Role
Executive Vice President
Signature
/s/ Lily J. Lu, Attorney-in-Fact for James F. Polewaczyk
Stock symbol
IDXX
Transactions as of
Feb 8, 2023
Transactions value $
$0
Form type
4
Date filed
2/10/2023, 04:03 PM
Previous filing
Feb 16, 2022
Next filing
Feb 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding IDXX Common Stock 15.4K Feb 8, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IDXX Non-Qualified Stock Option (right-to-buy) Award +6.24K 6.24K Feb 8, 2023 Common Stock 6.24K $497.43 Direct F2, F5
transaction IDXX Incentive Stock Option (right-to-buy) Award +201 201 Feb 8, 2023 Common Stock 201 $497.43 Direct F3, F5
transaction IDXX Restricted Stock Unit Award +880 +41.73% 2.99K Feb 8, 2023 Common Stock 880 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes a total of 55 shares purchased under the Issuer's Employee Stock Purchase Plan on March 31, 2022, June 30, 2022, September 30, 2022 and December 31, 2022.
F2 Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2024.
F3 Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2027.
F4 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024.
F5 Not applicable.